C4 Therapeutics, Inc. — 2020 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2020. This is an annual filing; it does not provide standalone fourth-quarter financial results. C4 Therapeutics is an early-stage biopharmaceutical company developing targeted protein degraders using its TORPEDO platform. It had no approved products and generated no product-sales revenue.
Business context and pipeline
The company’s lead candidate, CFT7455, targets IKZF1/3 for multiple myeloma and certain non-Hodgkin lymphomas. It filed an IND in December 2020 and reported FDA clearance in January 2021, with a Phase 1/2 trial planned for the first half of 2021. CFT8634, targeting BRD9 for synovial sarcoma and SMARCB1-deleted tumors, remained preclinical; an IND was planned for the second half of 2021 and a trial for 2022. BRAF V600E and RET programs were also in development, with clinical entry targeted by the end of 2022. These are company plans, not clinical outcomes.
Key financial metrics
| Metric | 2020 | 2019 |
|---|---|---|
| Collaboration revenue | $33.2 million | $21.4 million |
| Research and development expense | $78.4 million | $48.1 million |
| General and administrative expense | $15.2 million | $8.8 million |
| Total operating expenses | $93.6 million | $56.8 million |
| Operating loss | $60.4 million | $35.5 million |
| Net loss | $66.3 million | $34.1 million |
| Net loss per share, basic and diluted | $5.83 | $31.03 |
| Net cash used in operating activities | $67.2 million | Net cash provided: $55.6 million |
At year-end, cash and cash equivalents were $181.7 million and marketable securities were $190.0 million, for combined cash, cash equivalents and marketable securities of approximately $371.7 million. Current assets were $381.0 million versus current liabilities of $43.9 million. Long-term debt had $12.5 million principal outstanding and a $10.1 million carrying value. The company reported an accumulated deficit of $183.8 million. No product gross margin was reported; operating results reflect collaboration revenue and substantial R&D spending.
Material changes versus 2019
- Collaboration revenue increased $11.8 million, about 55%, led by higher activity and a milestone under the Biogen agreement.
- R&D expense increased $30.4 million, about 63%, mainly from preclinical development, IND-related work and personnel. G&A expense rose $6.4 million, including public-company costs.
- Net loss increased $32.2 million as operating costs rose and other income shifted to expense. 2020 included a $5.7 million noncash warrant fair-value charge and $1.2 million in debt interest and amortization; 2019 included $2.2 million of interest and other income.
- Operating cash flow shifted from $55.6 million provided in 2019 to $67.2 million used in 2020. The 2019 inflow was substantially affected by collection of collaboration-related receivables.
Liquidity, financing and outlook
Financing in 2020 included $145.5 million net proceeds from Series B preferred stock, $191.2 million net proceeds from the IPO, and $12.0 million net proceeds from debt. Preferred shares converted to common stock upon the October 2020 IPO. Management estimated that available funds and anticipated collaboration payments would support operations through the end of 2023, but cautioned that the estimate depends on assumptions and that additional capital will be needed to fund candidates through approval. Separately, the financial-statement note says year-end funds were sufficient for at least the next 12 months.
The $20.0 million secured credit facility included $12.5 million drawn and a further $7.5 million available subject to terms, with the draw window ending June 30, 2021. It carries a variable interest rate and is secured by substantially all company assets, including intellectual property; the agreement imposes covenants and a minimum controlled-account cash balance. Management expected continuing losses and rising expenses as programs advance.
Risks, contingencies and unusual items
- The platform and drug candidates were unproven clinically; most programs remained preclinical, and there was no assurance of safety, efficacy, approval or commercialization.
- COVID-19 had caused laboratory and CRO closures, shipping and manufacturing delays, and increased development uncertainty. The company said operational redundancies and remote work helped mitigate disruption.
- The company relied on third-party manufacturers and CROs, including single-source suppliers for some materials, and reported a prior fill/finish manufacturing issue that did not delay the CFT7455 IND filing.
- Roche, Biogen and Calico collaborations provided funding and potential milestone and royalty opportunities, but partners generally controlled later development and could terminate or discontinue programs. Aggregate upfront and milestone payments received from collaborators through year-end were reported as $167.5 million.
- The company reported no material legal proceedings. A 2019 material weakness in segregation of journal-entry duties was reported as remediated in 2020; management concluded disclosure controls were effective at the reasonable-assurance level. The 10-K did not include an auditor attestation on internal control.
- The company’s cash runway depends on spending, clinical progress, collaboration receipts and financing access; the filing states it will need substantial additional funding.
Most important facts for investors to verify
- Whether CFT7455 and CFT8634 meet the stated IND, trial-initiation and data milestones, and whether human safety and activity support the preclinical claims.
- Actual cash burn and subsequent cash, equivalents and marketable securities compared with management’s end-of-2023 runway estimate; note the separate “at least 12 months” statement.
- Terms, covenant compliance, repayment schedule and any further draw under the Perceptive secured facility, including the collateral and prepayment provisions.
- Progress, target decisions and payment conditions under the Roche, Biogen and Calico agreements, including any changes to collaboration scope or economics.
- Manufacturing capacity, supplier concentration and any COVID-19-related or other delays that affect clinical supply or trial timelines.
- Post-IPO share count, outstanding options and warrant, and potential dilution from future financing or equity awards.